Developer docs
API playgroundTry for free, no card

Search company profiles

CSSi LifeSciences

Full company profile

uuid000bwdl

Namestring
CSSi LifeSciences
Legal namestring
QNova LifeSciences
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLinthicum Heights, United States
HQ citystring
Linthicum Heights
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory consulting services, medical device consulting, drug development services, FDA approval consulting, clinical research services
Industry4 codes
PRIMARYHLAGAKAB
CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAG
Computer System Validation (CSV) & GxP IT Compliance (21 CFR Part 11/Annex 11)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAOAC
Medical Writing & Clinical Documentation FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
  • Management Consulting Services54161
SIC code2 codes
  • Services-Management Consulting Services8742
  • Services-Commercial Physical & Biological Research8731
Product category
Regulatory Affairs Consulting (Drugs and Medical Devices)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Regulatory Consulting Services
TypeProfessional Services
Description

The company generates revenue through providing regulatory consulting and management services for drug and medical device companies seeking FDA approval. Services include strategic pathway development, health authority meetings, submission services, quality management systems, and medical writing.

qnovals.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CSSi LifeSciences (now operating as QNova LifeSciences) is a global CRO and consulting group that provides customized regulatory, clinical, and commercialization solutions to advance therapeutics and medical devices through FDA approval and U.S. market entry. The firm delivers end-to-end services including regulatory strategy, submission preparation, medical writing, quality management systems, clinical trial management, project management, and U.S. market commercialization support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% Class 1 and 2 medical device approvals by U.S. FDA
+4 more records
Product overview1 text field

CSSi LifeSciences (now QNova LifeSciences) is a global CRO and consulting group specializing in advancing therapeutics and medical devices through development and regulatory approval. The company offers a unified platform of regulatory solutions including Drug Development Solutions, Medical Devices Solutions, Regulatory Services, Medical Writing, Quality Management Systems, and Commercialization Solutions (including U.S. Commercialization). The integrated service portfolio is complemented by Clinical Services and Strategy/Project Management capabilities to guide clients from discovery through commercialization, with particular focus on U.S. FDA approval processes.

Product and service8 records
1Drug Development Solutions
CategoryRegulatory Consulting
Description

Strategic pathway, consulting, planning and gap assessment, health authority meetings, and submission services for drug development through FDA approval. Designed for drug developers seeking IND, NDA, BLA, 505(b)1, and 505(b)2 submissions.

2Medical Devices Solutions
CategoryRegulatory Consulting
Description

Comprehensive regulatory consulting for medical devices including strategic pathway, planning, health authority meetings, and submission services through FDA CDRH. Targeted at medical device developers seeking Class I and II device approvals.

3Regulatory Services
CategoryRegulatory Consulting
Description

Expert guidance through the FDA approval process for novel drugs and medical devices, providing strategic regulatory consulting across drug and medical device programs.

4Medical Writing
CategoryRegulatory Consulting
Description

Professional medical writing services for regulatory submissions and documentation supporting FDA submissions for drugs and medical devices.

5Quality Management Systems
CategoryRegulatory Consulting
Description

Quality management system consulting and implementation supporting regulatory compliance for drug and medical device companies.

6U.S. Commercialization
CategoryCommercialization Consulting
Description

Comprehensive suite of customized services to help international life science companies enter the U.S. market and understand FDA regulations and business practices. Targeted at international companies seeking U.S. market entry.

7Clinical Services
CategoryClinical Research Services
Description

Clinical development services across all clinical phases to transform new drug or medical device entities into treatment opportunities, leveraging access to 700+ clinical sites.

8Strategy and Project Management
CategoryStrategy and Management Consulting
Description

Risk-based strategic roadmap providing an integrated and adaptive pathway to commercialization that mitigates time and cost across development, regulatory, clinical, and commercial phases.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Academic Incubators and Accelerators
Strategic tierCoreTypeOthers
Description

CSSi LifeSciences has partnered with over 15 academic incubators and accelerators. These partnerships support life science entrepreneurship by providing ecosystem services for early technology development and advancing strategic objectives for companies entering the U.S. market.

qnovals.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ProPharma Group is a regulatory, compliance, and pharmacovigilance consulting firm serving pharma and medical device developers, directly overlapping with QNova's regulatory consulting, quality management systems, and medical writing offerings.

2NAMSA
TypeDirect peer
Description

NAMSA is a medical device-focused CRO offering regulatory, clinical, and quality consulting services. Like QNova, it serves device manufacturers navigating FDA CDRH approval pathways and combines consulting with operational trial support.

TypeDirect peer
Description

Medpace is a mid-sized global CRO providing clinical development and regulatory services across all phases, comparable to QNova's clinical and regulatory portfolio for drugs and devices.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized CRO offering clinical and post-approval services across therapeutic areas, operating with a similar boutique-style, sponsor-focused model as QNova.

TypeDirect peer
Description

CTI is a CRO providing clinical trial management, regulatory consulting, and therapeutic expertise, with comparable scale and a multi-therapeutic focus similar to QNova's service range.

6Veristat
TypeEmerging player
Description

Veristat is a smaller, regulatory-focused CRO offering biostatistics, clinical, and submission services for drugs and biologics, with narrower scope than QNova but overlapping regulatory submission expertise.

TypeDirect peer
Description

Celerion is a CRO specializing in early-phase clinical research and bioanalytical services, comparable to the clinical development portion of QNova's offering for drug developers.

TypeBroad incumbent
Description

IQVIA is the largest global CRO offering end-to-end clinical, regulatory, and commercial services across drugs and devices. It competes broadly with QNova but operates at vastly greater scale and across all geographies.

TypeBroad incumbent
Description

ICON plc is a leading global CRO providing clinical, regulatory, and consulting services to pharma and device sponsors, with overlapping capabilities but broader portfolio and global reach than QNova.

TypeBroad incumbent
Description

Charles River Laboratories is a large CRO offering discovery, preclinical, clinical, and regulatory services, with overlapping capabilities to QNova but a much broader portfolio and global footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CSSi LifeSciences

Regulatory Affairs Consulting (Drugs and Medical Devices)cssilifesciences.com

CSSi LifeSciences firmographics

Firmographics
Name
CSSi LifeSciences
Legal name
QNova LifeSciences
Website
https://cssilifesciences.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

CSSi LifeSciences industry classification

Industry
Product category
Regulatory Affairs Consulting (Drugs and Medical Devices)
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAB
CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAG
Computer System Validation (CSV) & GxP IT Compliance (21 CFR Part 11/Annex 11)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAOAC
Medical Writing & Clinical Documentation FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Regulatory consulting services
  • Medical device consulting
  • Drug development services
  • FDA approval consulting
  • Clinical research services

Where CSSi LifeSciences is headquartered

Location

Headquarters

HQ city
Linthicum Heights
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CSSi LifeSciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Regulatory Consulting Services: The company generates revenue through providing regulatory consulting and management services for drug and medical device companies seeking FDA approval. Services include strategic pathway development, health authority meetings, submission services, quality management systems, and medical writing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

CSSi LifeSciences product offering

Product offering

Core offering

CSSi LifeSciences (now operating as QNova LifeSciences) is a global CRO and consulting group that provides customized regulatory, clinical, and commercialization solutions to advance therapeutics and medical devices through FDA approval and U.S. market entry. The firm delivers end-to-end services including regulatory strategy, submission preparation, medical writing, quality management systems, clinical trial management, project management, and U.S. market commercialization support.

Product overview

CSSi LifeSciences (now QNova LifeSciences) is a global CRO and consulting group specializing in advancing therapeutics and medical devices through development and regulatory approval. The company offers a unified platform of regulatory solutions including Drug Development Solutions, Medical Devices Solutions, Regulatory Services, Medical Writing, Quality Management Systems, and Commercialization Solutions (including U.S. Commercialization). The integrated service portfolio is complemented by Clinical Services and Strategy/Project Management capabilities to guide clients from discovery through commercialization, with particular focus on U.S. FDA approval processes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Development Solutions Strategic pathway, consulting, planning and gap assessment, health authority meetings, and submission services for drug development through FDA approval. Designed for drug developers seeking IND, NDA, BLA, 505(b)1, and 505(b)2 submissions.
  • Medical Devices Solutions Comprehensive regulatory consulting for medical devices including strategic pathway, planning, health authority meetings, and submission services through FDA CDRH. Targeted at medical device developers seeking Class I and II device approvals.
  • Regulatory Services Expert guidance through the FDA approval process for novel drugs and medical devices, providing strategic regulatory consulting across drug and medical device programs.
  • Medical Writing Professional medical writing services for regulatory submissions and documentation supporting FDA submissions for drugs and medical devices.
  • Quality Management Systems Quality management system consulting and implementation supporting regulatory compliance for drug and medical device companies.
  • U.S. Commercialization Comprehensive suite of customized services to help international life science companies enter the U.S. market and understand FDA regulations and business practices. Targeted at international companies seeking U.S. market entry.
  • Clinical Services Clinical development services across all clinical phases to transform new drug or medical device entities into treatment opportunities, leveraging access to 700+ clinical sites.
  • Strategy and Project Management Risk-based strategic roadmap providing an integrated and adaptive pathway to commercialization that mitigates time and cost across development, regulatory, clinical, and commercial phases.

Quantifiable outcome

  • 100% Class 1 and 2 medical device approvals by U.S. FDA
  • +4 more outcomes

Companies that use CSSi LifeSciences

Customer profile

Segments2 records

Ideal customer profiles2 records

CSSi LifeSciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CSSi LifeSciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Academic Incubators and AcceleratorscoreOthersCSSi LifeSciences has partnered with over 15 academic incubators and accelerators. These partnerships support life science entrepreneurship by providing ecosystem services for early technology development and advancing strategic objectives for companies entering the U.S. market.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

CSSi LifeSciences competitors and assessment

Company assessment

Direct peers

  • ProPharma Group: ProPharma Group is a regulatory, compliance, and pharmacovigilance consulting firm serving pharma and medical device developers, directly overlapping with QNova's regulatory consulting, quality management systems, and medical writing offerings.
  • NAMSA: NAMSA is a medical device-focused CRO offering regulatory, clinical, and quality consulting services. Like QNova, it serves device manufacturers navigating FDA CDRH approval pathways and combines consulting with operational trial support.
  • Medpace: Medpace is a mid-sized global CRO providing clinical development and regulatory services across all phases, comparable to QNova's clinical and regulatory portfolio for drugs and devices.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO offering clinical and post-approval services across therapeutic areas, operating with a similar boutique-style, sponsor-focused model as QNova.
  • CTI Clinical Trial & Consulting Services: CTI is a CRO providing clinical trial management, regulatory consulting, and therapeutic expertise, with comparable scale and a multi-therapeutic focus similar to QNova's service range.
  • Celerion: Celerion is a CRO specializing in early-phase clinical research and bioanalytical services, comparable to the clinical development portion of QNova's offering for drug developers.

Emerging players

  • Veristat: Veristat is a smaller, regulatory-focused CRO offering biostatistics, clinical, and submission services for drugs and biologics, with narrower scope than QNova but overlapping regulatory submission expertise.

Broad incumbents

  • IQVIA: IQVIA is the largest global CRO offering end-to-end clinical, regulatory, and commercial services across drugs and devices. It competes broadly with QNova but operates at vastly greater scale and across all geographies.
  • ICON plc: ICON plc is a leading global CRO providing clinical, regulatory, and consulting services to pharma and device sponsors, with overlapping capabilities but broader portfolio and global reach than QNova.
  • Charles River Laboratories: Charles River Laboratories is a large CRO offering discovery, preclinical, clinical, and regulatory services, with overlapping capabilities to QNova but a much broader portfolio and global footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CSSi LifeSciences social profiles

Digital presence

CSSi LifeSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CSSi LifeSciences leadership team

Management profile

Number of profiles

Profiles1 record

CSSi LifeSciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CSSi LifeSciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSSi LifeSciences

What does CSSi LifeSciences do?

CSSi LifeSciences (now operating as QNova LifeSciences) is a global CRO and consulting group that provides customized regulatory, clinical, and commercialization solutions to advance therapeutics and medical devices through FDA approval and U.S. market entry. The firm delivers end-to-end services including regulatory strategy, submission preparation, medical writing, quality management systems, clinical trial management, project management, and U.S. market commercialization support.

Is CSSi LifeSciences a public or private company?

CSSi LifeSciences is a private company. It is classified as unknown and is currently operating.

When was CSSi LifeSciences founded?

CSSi LifeSciences was founded in -1. It employs 11 to 50 people.

Where is CSSi LifeSciences based?

CSSi LifeSciences is headquartered in Linthicum Heights, United States, in the North America region.

How does CSSi LifeSciences make money?

One revenue line is on record: regulatory Consulting Services.

Who are CSSi LifeSciences's main competitors?

Direct peers on record are ProPharma Group, NAMSA, Medpace, Worldwide Clinical Trials, CTI Clinical Trial & Consulting Services and Celerion. Veristat is listed as an emerging player. Broad incumbents are IQVIA, ICON plc and Charles River Laboratories.

Does CSSi LifeSciences have an API?

No public API is recorded for CSSi LifeSciences.

What industry is CSSi LifeSciences in?

CSSi LifeSciences's product category is Regulatory Affairs Consulting (Drugs and Medical Devices). Its primary akta.pro industry code is HLAGAKAB, CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5417 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireCSSi LifeSciences Announces Rebrand to QNova LifeSciencesCSSi LifeSciences announced its rebrand to QNova LifeSciences, a global regulatory consulting firm for drug and medical device companies. The new name reflects its expanded services, including QNova Accelerator and QNova Capital, while the team and commitment remain unchanged.PR NewswireSiSaf's Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug DesignationSiSaf Ltd has initiated the U.S. FDA regulatory process to obtain Orphan Drug Designation for SIS-101-ADO, an siRNA therapeutic targeting Autosomal Dominant Osteopetrosis Type 2. The application is being coordinated by CSSi LifeSciences, leveraging SiSaf's proprietary Bio-Courier® technology for RNA delivery.PR NewswireTonic Bioventures and CSSi LifeSciences Enter Partnership to Form A New Life Sciences FundTonic Bioventures and CSSi LifeSciences announced the formation of a new life sciences venture fund on January 6, 2021. The fund aims to invest in 12 to 16 opportunities over three to five years, leveraging CSSi's regulatory expertise to accelerate medical technologies from proof-of-concept to commercialization.PR NewswireCSSi to Sponsor LGS Awareness EventCSSi announced it will sponsor the LGS Foundation's "Dive In to a Sea of Hope" fundraiser on October 28, 2017, at the National Aquarium in Baltimore, Maryland. The event aims to raise awareness for Lennox-Gastaut Syndrome, a rare and debilitating form of epilepsy affecting fewer than 50,000 individuals in the United States with no known cure. CSSi, a patient recruitment company for clinical trials, has completed over 150 CNS/neurology programs including more than 20 focused on epilepsy in pediatric and adolescent patients.PR NewswireGlobal Patient Recruitment Company CSSi Launches Redesigned WebsiteCSSi, a global patient recruitment company for the clinical research industry, announced on May 10, 2017 the launch of its newly redesigned website, www.CSSiEnroll.com, featuring improved navigation, streamlined content, and enhanced user experience. The company highlighted its track record of completing over 1,200 studies in the last three years across 17 therapeutic areas and 120 unique indications, coinciding with its 12-year anniversary. The website redesign effort focused on aesthetics, content simplification, and increasing brand visibility for the company.PR NewswireCSSi LifeSciences™ and BioMARC Announce Strategic Partnership to Provide a Single-Source Biopharmaceutical Manufacturing and Clinical SolutionCSSi LifeSciences and BioMARC, a nonprofit contract manufacturing unit owned by Colorado State University, announced a strategic partnership to provide integrated biopharmaceutical manufacturing and clinical solutions. The collaboration aims to combine CSSi's regulatory and clinical expertise with BioMARC's cGMP manufacturing capabilities to accelerate the development of biologics and vaccines.PR NewswireCSSi LifeSciences™ to Host Annual Partnering and Networking Event for Top Industry Executives and Investors in the Life SciencesCSSi LifeSciences announced its Partnering Forum 2017 at the J.P. Morgan Healthcare Conference in San Francisco, Jan. 9-12, 2017. The event offers networking with investors and executives, plus presentations on market and investment opportunities. The company has supported over 500 drug and device developments.PR NewswireCSSi LifeSciences™ to Host Annual Partnering and Networking Event for Top Industry Executives and Investors in the Life SciencesCSSi LifeSciences™ announced it will host its 2017 Partnering Forum during the J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2017. The event aims to connect life sciences companies with strategic investors and decision-makers through expert-led presentations and private meetings. Key partners for the forum include FOCUS Investment Banking, Polsinelli, and several other industry organizations.PR NewswireCSSi LifeSciences™ Launches Fully Integrated Medical Device CROCSSi LifeSciences™ has launched a fully integrated Medical Device CRO to assist companies in navigating regulatory clearance and accelerating product commercialization. The service leverages the team's extensive regulatory experience to help clients avoid delays and reduce costs associated with medical device development.PR NewswireCSSi LifeSciences and Innosphere Announce Pioneering Partnership to Deliver Innovative Medical and Drug Advancement SolutionsCSSi LifeSciences, a regulatory and clinical services provider headquartered in Maryland, announced a strategic partnership with Innosphere, a Colorado-based nonprofit technology incubator, to deliver medical device and drug development solutions to emerging life science companies in the state. Under the agreement, CSSi LifeSciences will provide Innosphere's client companies with regulatory, clinical, and commercial assessment services, along with education and training programs aimed at reducing development costs and accelerating time-to-market. The partnership was formally announced on August 11, 2016, at Innosphere's 'Innovation After Hours' networking forum.